Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
KPRX | US
-0.09
-2.65%
Healthcare
Biotechnology
30/06/2024
17/10/2024
3.31
3.43
3.58
3.31
Kiora Pharmaceuticals Inc. a clinical-stage specialty pharmaceutical company develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301 a potential vision-restoring small molecule which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101 an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis as well as for treating non-infectious posterior uveitis; and KIO-201 an eye drop which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals Inc. and changed its name to Kiora Pharmaceuticals Inc. in November 2021. Kiora Pharmaceuticals Inc. was incorporated in 1998 and is headquartered in Encinitas California.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
High Current Volume and Negative 1-Day Return
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
83.5%1 month
66.5%3 months
74.5%6 months
86.0%0.21
2.41
0.31
0.00
0.00
-1.03
569.41
-
6.32M
9.83M
9.83M
-
-12.12K
-
-
13.69
0.31
0.14
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.50
Range1M
0.80
Range3M
1.86
Rel. volume
2.33
Price X volume
109.14K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
TransCode Therapeutics Inc. Common Stock | RNAZ | Biotechnology | 0.599 | 10.78M | -11.79% | 0.00 | 17.19% |
Sensei Biotherapeutics Inc | SNSE | Biotechnology | 0.4237 | 10.66M | -7.69% | n/a | 9.67% |
RedHill Biopharma Ltd | RDHL | Biotechnology | 8.205 | 10.51M | -3.36% | n/a | 65.80% |
Alterity Therapeutics Limited | ATHE | Biotechnology | 1.2 | 10.49M | -4.00% | n/a | 1.15% |
GlycoMimetics Inc | GLYC | Biotechnology | 0.1585 | 10.22M | 1.02% | n/a | 2.24% |
SNTI | SNTI | Biotechnology | 2.15 | 9.84M | -1.83% | n/a | 80.96% |
BioCardia Inc | BCDA | Biotechnology | 2.65 | 9.46M | 0.57% | n/a | -58.03% |
Aptorum Group Limited | APM | Biotechnology | 1.66 | 9.08M | -1.78% | n/a | 13.53% |
Soligenix Inc | SNGX | Biotechnology | 3.63 | 8.47M | 2.83% | n/a | 84.28% |
Arsanis Inc | ASNS | Biotechnology | 1.4 | 8.43M | 1.45% | n/a | 252.35% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a | |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.54 | 0 | -1.56% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.03 | 0.53 | Cheaper |
Ent. to Revenue | 569.41 | 4,005.99 | Cheaper |
PE Ratio | 0.21 | 40.42 | Cheaper |
Price to Book | 0.31 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 74.46 | 72.92 | Par |
Debt to Equity | 0.00 | -1.24 | Expensive |
Debt to Assets | 0.00 | 0.25 | Cheaper |
Market Cap | 9.83M | 3.78B | Emerging |